Brief Report: Analysis of 4070A Envelope Levels in Retroviral Preparations and Effect on Target Cell Transduction Efficiency
- 1 July 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (10) , 1439-1451
- https://doi.org/10.1089/10430340050057512
Abstract
A number of stable producer cell lines for high-titer Mo-MuLV vectors have been constructed. Development has previously centered on increasing end-point titers by producing maximal levels of Mo-MuLV Gag/Pol, envelope glycoproteins, and retroviral RNA genomes. We describe the production yields and transduction efficiency characteristics of two Mo-MuLV packaging cell lines, FLYA13 and TEFLYA. Although they both produce 4070A-pseudotyped retroviral vectors reproducibly at > 1 X 106 LFU ml-1, the transduction efficiency of unconcentrated and concentrated virus from FLYA13 lines is poor compared with vector preparations from TEFLYA lines. A powerful inhibitor of retroviral transduction is secreted by FLYA13 packaging cells. We show that the inhibitory factor does not affect transduction of target cells by RD114-pseudotyped vectors. This suggests that the inhibitory factor functions at the level of envelope-receptor interactions. Phosphate starvation of target cells shows a two-fold increase in Pit2 receptor mRNA and causes some improvement in FLYA13 virus transduction efficiency. Western blots show that FLYA13 viral samples contain an eight-fold higher ratio of 4070A envelope to p30gag than that of virus produced by TEFLYA producer cell lines. This study correlates overexpression of 4070A envelope glycoprotein in retroviral preparations with a reduction of transduction efficiency at high multiplicities of infection. We suggest that TEFLYA packaging cells express preferable levels of 4070A compared with FLYA13, which not only enables high-titer stocks to be generated, but also facilitates a high efficiency of transduction of target cells.Keywords
This publication has 35 references indexed in Scilit:
- Retroviral Vectors for the Expression of Two Genes in Human Multipotent Neural Precursors and Their Differentiated Neuronal and Glial ProgenyHuman Gene Therapy, 1999
- RNA Levels of Human Retrovirus Receptors Pit1 and Pit2 Do Not Correlate with Infectibility by Three Retroviral Vector PseudotypesHuman Gene Therapy, 1998
- Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transferGene Therapy, 1997
- The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.Proceedings of the National Academy of Sciences, 1996
- A Simple and Efficient Method for the Concentration and Purification of Recombinant Retrovirus for Increased Hepatocyte TransductionIn VivoHuman Gene Therapy, 1996
- HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Nature, 1996
- A transient three-plasmid expression system for the production of high titer retroviral vectorsNucleic Acids Research, 1995
- A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family.Proceedings of the National Academy of Sciences, 1994
- Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus.Proceedings of the National Academy of Sciences, 1994
- Polypeptides of mammalian oncornavirusesVirology, 1975